Wyeth Receives Approvable Letter From FDA For Bazedoxifene For The Treatment Of Postmenopausal Osteoporosis

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis. In the letter, the FDA requested information similar to that outlined in its approvable letter for bazedoxifene’s New Drug Application (NDA) for the prevention of postmenopausal osteoporosis issued in December 2007.

More: continued here

Filed under: Bones on June 1st, 2008